Breaking News
January 19, 2018 - ‘You’re Old and You Need Tests’: What We Heard This Week
January 19, 2018 - Egg-preserving hysterectomy raises heart risks later: study
January 19, 2018 - GA-map Dysbiosis Test identifies IBS patients who respond to FODMAP diet, study shows
January 19, 2018 - Study explores mortality and health-related habits in former elite athletes and their brothers
January 19, 2018 - New biodegradable sensors could assist doctors
January 19, 2018 - Modular gene enhancers may be suitable target in treatment of blood cancer
January 18, 2018 - New precision medicine trial for metastatic pancreatic cancer
January 18, 2018 - Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients
January 18, 2018 - Pre-Existing Patient-Valve Mismatch Trips Up ViV Implant
January 18, 2018 - Adolescents: health risks and solutions
January 18, 2018 - US woman delivers baby from embryo frozen for 24 years
January 18, 2018 - Study identifies new target for treatment of depression
January 18, 2018 - LJI study reveals key player that promotes skin inflammation in atopic dermatitis
January 18, 2018 - Study devises efficient and economical strategy to screen breast and ovarian cancer gene mutations
January 18, 2018 - Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the Prevention of Pregnancy
January 18, 2018 - Gene Therapy for Inherited Retinal Dystrophy Gets FDA Clearance
January 18, 2018 - Researchers identify a new chemical pathway that helps the brain detect sweet, savory and bitter flavors
January 18, 2018 - IBV develops platform that helps companies to diagnose wellbeing of their workforce
January 18, 2018 - Study to test new precision medicine approach for metastatic pancreatic cancer
January 18, 2018 - World’s first vaccine relieves grass pollen allergy symptoms by at least 25%, study shows
January 18, 2018 - FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC
January 18, 2018 - Oncologists Dish on Top Issues for 2018
January 18, 2018 - Researchers identify new potential drug target for Huntington’s disease
January 18, 2018 - Metrohm USA welcomes employees to new headquarters in Florida
January 18, 2018 - Human waste remains main source of fecal pollution in the river Danube
January 18, 2018 - Expert discusses how to stay healthy during flu season
January 18, 2018 - New biomaterials-based system improves T-cell production
January 18, 2018 - Novel gene expression analysis technique can accurately and quickly measure RNA
January 18, 2018 - Grandparents Help Shape Kids’ Views on Aging
January 18, 2018 - Absolutely Zero Stent Thrombosis at 5 Years With Bioabsorbable MiStent
January 18, 2018 - Safe Sleep for Babies | VitalSigns
January 18, 2018 - Pfizer to launch own little white pill
January 18, 2018 - Aged garlic extract may help obese people fight against inflammation, study shows
January 18, 2018 - Sex steroid hormone fluctuations may have direct effects on eye physiology and AMD
January 18, 2018 - Patients with monoclonal gammopathy at risk of developing cancer even after 30 years
January 18, 2018 - Researchers reveal potential of multivalent antibodies for HIV prevention, treatment and cure
January 18, 2018 - Dying cancer patients receiving assisted hydration live longer
January 18, 2018 - Potential male birth control pill could be developed from arrow poison
January 18, 2018 - Research reveals cost-effectiveness of whole-population screening for breast, ovarian cancer gene mutations
January 18, 2018 - Genes involved in spinal cord repair of lamprey also present in mammals, study reveals
January 18, 2018 - Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
January 18, 2018 - The State of the Drug Discovery Nation Unveiled as New Report Provides Vital Insights for the Development of New Medicines
January 18, 2018 - Dutch Study Links Implants to Increased Breast-ALCL Risk
January 18, 2018 - Five addiction experts weigh in on future of opioid crisis. Their forecast: grim
January 18, 2018 - EXD2 enzyme facilitates protein production in mitochondria
January 18, 2018 - Kessler Foundation wins $735,000 grant for training rehabilitation researchers
January 18, 2018 - Researchers find new way to halt growth of breast cancer cells
January 18, 2018 - Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
January 18, 2018 - Civilians Now Getting Flu-Like Illness Afflicting Troops
January 18, 2018 - Discovery brings stem cell therapy for eye disease closer to the clinic
January 18, 2018 - Guts of surfers more likely to be colonized by antibiotic-resistant bacteria, study reveals
January 18, 2018 - Bacteria linked to periodontitis may play role in onset of cancer
January 18, 2018 - Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
January 18, 2018 - Early Menarche, Menopause Tied to Higher CVD Risk
January 18, 2018 - Pioneering new technique could boost understanding of causes of heart disease
January 18, 2018 - New brain imaging techniques show how infants’ brains process ‘touch’
January 18, 2018 - GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older
January 18, 2018 - Blood Markers Point to Maladaptive LV Remodeling
January 18, 2018 - Effect of gut bacteria on specific immune cells underlies persistent liver inflammation
January 18, 2018 - Study reveals new diabetes gene in families with rare blood sugar conditions
January 18, 2018 - Fewer Hospitals Closed After Obamacare Expanded Medicaid
January 18, 2018 - At-Home Breath Training Improves Asthma Quality of Life
January 18, 2018 - Obesity can add five weeks of asthma symptoms per year in preschoolers
January 18, 2018 - Neuronal loss is very limited in Alzheimer’s disease, shows new study
January 18, 2018 - A new strategy proposed for drug discovery
January 17, 2018 - Lactation May Lower T2D Risk in Younger Women
January 17, 2018 - New Atopic Dermatitis Yardstick provides practical guidance and management insights
January 17, 2018 - New biodegradable pressure sensor could help monitor serious health conditions
January 17, 2018 - HSS orders Sectra’s 3D pre-operative planning solution for improving patient outcomes
January 17, 2018 - Study identifies six new genes regions associated with diabetes
January 17, 2018 - Women do not receive timely diagnosis for heart disease
January 17, 2018 - AbbVie’s Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
January 17, 2018 - Should President Trump’s Physical Include a Cognitive Screen?
January 17, 2018 - Could gene therapy someday eliminate HIV?
January 17, 2018 - Researchers identify new anti-inflammatory drug target
January 17, 2018 - Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
January 17, 2018 - Trunk Imaging Tied to Higher Nephrectomy Risk
January 17, 2018 - Campaigners incensed at failings in Africa AIDS war
January 17, 2018 - Research opens door to development of new treatment for type 2 diabetes
January 17, 2018 - Uniqsis’ novel reactor system for continuous flow synthesis
Study finds medical cannabis is effective at reducing opioid addiction

Study finds medical cannabis is effective at reducing opioid addiction

image_pdfDownload PDFimage_print
Credit: University of New Mexico

A new study conducted by researchers at The University of New Mexico, involving medical cannabis and prescription opioid use among chronic pain patients, found a distinct connection between having the legal ability to use cannabis and significant reductions in opioid use.

The study, titled “Associations between Medical Cannabis and Prescription Opioid Use in Chronic Pain Patients: A Preliminary Cohort Study,” and published in the open access journal PLOS ONE, was conducted by Drs. Jacob Miguel Vigil, associate professor, Department of Psychology and Sarah See Stith, assistant professor, Department of Economics. The results from this preliminary study showed a strong correlation between enrollment in the New Mexico Medical Cannabis Program (MCP) and cessation or reduction of opioid use, and that whole, natural Cannabis sativa and extracts made from the plant may serve as an alternative to opioid-based medications for treating chronic pain.

Today, opioid-related drug overdoses are the leading cause of preventable deaths in the United States killing approximately 100 Americans every day. Conventional pharmaceutical medications for treating opioid addiction, such as methadone and buprenorphine-tapering, can be similarly dangerous due to substantial risks of lethal drug interactions and overdose.

“Current levels and dangers of opioid use in the U.S. warrant the investigation of harm-reducing treatment alternatives,” said Vigil, who led the study. “Our results highlight the necessity of more extensive research into the possible uses of cannabis as a substitute for opioid painkillers, especially in the form of placebo-based, randomized controlled trials and larger sample observational studies.”

Cannabis has been investigated as a potential treatment for a wide range of medical conditions from post-traumatic stress disorder to cancer, with the most consistent support for the treatment of chronic pain, epilepsy and spasticity. In the U.S., states, including New Mexico, have enacted MCPs in part for people with chronic, debilitating pain who cannot be adequately or safely treated with conventional pharmaceutical medications.

Like other states, New Mexico only permits medical cannabis use for patients with certain debilitating medical conditions. All the patients in the study had a diagnosis of “severe chronic pain,” annually validated by two independent physicians, including a board-certified specialist.

New Mexico, Vigil notes, is among the U.S. states hardest hit by the current opioid epidemic, although the number of opioid-related overdose deaths appears to have fallen in recent years, perhaps the result of increased enrollment in the NM MCP, which currently includes more than 48,000 patients.

“MCPs are unique, not only because they allow patients to self-manage their cannabis treatment, but because they operate in conflict with U.S. federal law, making it challenging for researchers to utilize conventional research designs to measure their efficacy,” Vigil said.

The purpose of the researchers’ preliminary, cohort study was to help examine the association between enrollment in a MCP and opioid prescription use. The study observed 37 habitual opioid using, chronic pain patients that chose to enroll in the MCP between 2010 and 2015, compared to 29 patients with similar health conditions that were also given the option, but ultimately chose not to enroll in the MCP.

“Using informal surveys of patients enrolled in the MCP, we discovered a significant proportion of chronic pain patients reporting to have substituted their opioid prescriptions with cannabis for treating their chronic pain,” said Vigil.

The researchers used Prescription Monitoring Program opioid records over a 21-month observation period (first three months prior to enrollment for the MCP patients) to more objectively measure opioid cessation – defined as the absence of opioid prescriptions activity during the last three months of observation, with use calculated in average daily intravenous [IV] morphine dosages. MCP patient-reported benefits and side effects of using cannabis one year after enrollment were also collected.

By the end of the observation period, the data showed MCP enrollment was associated with a 17 times higher age- and gender-adjusted odds of ceasing opioid prescriptions, a 5 times higher odds of reducing daily prescription opioid dosages, and a 47 percentage point reduction in daily opioid dosages relative to a mean change of positive 10 percentage points in the non-enrolled patient group.

Survey responses indicated improvements in pain reduction, quality of life, social life, activity levels, and concentration, and few negative side effects from using cannabis one year after enrollment in the MCP.

The researchers’ findings, which provide clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrant further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.

According to Stith, “The economic impact of cannabis treatment should also be considered given the current burden of opioid prescriptions on healthcare systems, which have been forced to implement costly modifications to general patient care practices, including prescription monitoring programs, drug screening, more frequent doctor-patient interactions, treatment of drug abuse and dependence, and legal products and services associated with limiting opioid-related liability.”

“If cannabis can serve as an alternative to prescription opioids for at least some patients, legislators and the medical community may want to consider medical cannabis programs as a potential tool for combating the current opioid epidemic,” Vigil said.


Explore further:
Study finds legal cannabis may reduce use of dangerous prescription drugs

More information:
“Associations between Medical Cannabis and Prescription Opioid Use in Chronic Pain Patients: A Preliminary Cohort Study,” PLOS ONE, 2017. digitalrepository.unm.edu/psych_data/1/

Journal reference:
PLoS ONE

Provided by:
University of New Mexico

Tagged with:

About author

Related Articles